Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.8 USD | -1.64% | +7.14% | +104.55% |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 226M |
---|---|---|---|---|---|
Net income 2023 * | -30M | Net income 2024 * | -32M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-7.5
x | P/E ratio 2024 * |
-6.92
x | Employees | 11 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 98.92% |
Latest transcript on Atossa Therapeutics, Inc.
1 day | -1.64% | ||
1 week | +7.14% | ||
Current month | +84.24% | ||
1 month | +80.00% | ||
3 months | +84.41% | ||
6 months | +138.41% | ||
Current year | +104.55% |
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.8 | -1.64% | 1,890,373 |
24-03-27 | 1.83 | +1.67% | 2,548,777 |
24-03-26 | 1.8 | -4.76% | 3,789,850 |
24-03-25 | 1.89 | +13.17% | 3,230,483 |
24-03-22 | 1.67 | -0.60% | 1,869,631 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+104.55% | 226M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |